Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis
| Autor: | van der Tjipke Werf, J A Dijkstra, Jos G. W. Kosterink, Onno W. Akkerman, R. van Altena, Johannes H. Proost, de Wiel Lange, Jan-Willem C. Alffenaar |
|---|---|
| Přispěvatelé: | Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Center for Liver, Digestive and Metabolic Diseases (CLDM), Microbes in Health and Disease (MHD), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), Clinical pharmacology and pharmacy |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty OTOTOXICITY Population Antitubercular Agents DOSING REGIMEN Biostatistics Pharmacology TOXICITY Specimen Handling Young Adult Limited sampling Pharmacokinetics Kanamycin Interquartile range Moxifloxacin Internal medicine Tuberculosis Multidrug-Resistant medicine Humans Tuberculosis Pharmacology (medical) MOXIFLOXACIN Dosing education Amikacin Retrospective Studies DOSAGE education.field_of_study Models Statistical NEPHROTOXICITY medicine.diagnostic_test business.industry General Medicine biochemical phenomena metabolism and nutrition POPULATION PHARMACOKINETICS carbohydrates (lipids) Infectious Diseases Therapeutic drug monitoring Female Pharmacokinetic model Drug Monitoring business medicine.drug |
| Zdroj: | International journal of antimicrobial agents, 46(3), 332-337. Elsevier Bedrijfsinformatie b.v. International Journal of Antimicrobial Agents, 46(3), 332-7. Elsevier Dijkstra, J A, van Altena, R, Akkerman, O W, de Lange, W C M, Proost, J H, van der Werf, T S, Kosterink, J G W & Alffenaar, J W C 2015, ' Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis ', International Journal of Antimicrobial Agents, vol. 46, no. 3, pp. 332-7 . https://doi.org/10.1016/j.ijantimicag.2015.06.008 |
| ISSN: | 0924-8579 |
| DOI: | 10.1016/j.ijantimicag.2015.06.008 |
| Popis: | Amikacin and kanamycin are considered important and effective drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB). Unfortunately, the incidence of toxicity is high and is related to elevated drug exposure. In order to achieve a balance between efficacy and toxicity, a population pharmacokinetic (PPK) model may help to optimise drug exposure. Patients with MDR-TB who had received amikacin or kanamycin as part of their treatment and who had routinely received therapeutic drug monitoring were evaluated. A PPK model was developed and subsequently validated. Using this model, a limited sampling model was developed. Eleven patients receiving amikacin and nine patients receiving kanamycin were included in this study. The median observed 24-h area under the concentration-time curve (AUC(0-24h)) was 77.2 mg h/L [interquartile range (IQR) 64.7-96.2 mg h/L] for amikacin and 64.1 mg h/L (IQR 55.6-92.1 mg h/L) for kanamycin. The PPK model was developed and validated using n-1 cross-validation. A robust population model was developed that is suitable for predicting the AUC(0-24h) of amikacin and kanamycin. This model, in combination with the limited sampling strategy developed, can be used in daily routine to guide dosing but also to assess AUC0_24h in phase 3 studies. (C) 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect